Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ^null mice treated with alogliptin

References

• Drucker DJ Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis Mol Endocrinol 2003 17 2 161 171 12554744
   PubMed Web of Science ®Google Scholar
• Egan JM Bulotta A Hui H Perfetti R GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells Diabetes Metab Res Rev 2003 19 2 115 123 12673779
   PubMed Web of Science ®Google Scholar
• Kim D MacConell L Zhuang D Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 2007 30 6 1487 1493 17353504
   PubMed Web of Science ®Google Scholar
• Vilsbøll T Zdravkovic M Le-Thi T Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes Diabetes Care 2007 30 6 1608 1610 17372153
   PubMed Web of Science ®Google Scholar
• Rother KI Spain LM Wesley RA Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes Diabetes Care 2009 32 12 2251 2257 19808924
   PubMed Web of Science ®Google Scholar
• Buse JB Henry RR Han J Kim DD Fineman MS Baron AD Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 11 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 5 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 5 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• Peters A Incretin-based therapies: review of current clinical trial data Am J Med 2010 123 Suppl 3 S28 S37 20206729
   PubMed Web of Science ®Google Scholar
• Herman GA Stein PP Thornberry NA Wagner JA Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin Clin Pharmacol Ther 2007 81 5 761 767 17392725
   PubMed Web of Science ®Google Scholar
• Aschner P Kipnes MS Lunceford JK Sanchez M Mickel C Williams-Herman DE Sitagliptin Study 021 Group Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 2006 29 12 2632 2637 17130196
   PubMed Web of Science ®Google Scholar
• Shultz LD Lyons BL Burzenski LM Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells J Immunol 2005 174 10 6477 6489 15879151
   PubMed Web of Science ®Google Scholar
• Shultz LD Ishikawa F Greiner DL Humanized mice in translational biomedical research Nat Rev Immunol 2007 7 2 118 130 17259968
   PubMed Web of Science ®Google Scholar
• Feng J Zhang Z Wallace MB Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV J Med Chem 2007 50 10 2297 2300 17441705
   PubMed Web of Science ®Google Scholar
• Andukuri R Drincic A Rendell M Alogliptin: a new addition to the class of DPP-4 inhibitors Diabetes Metab Syndr Obes 2009 2 117 126 21437125
   PubMedGoogle Scholar
• Scott LJ Alogliptin: a review of its use in the management of type 2 diabetes mellitus Drugs 2010 70 15 2051 2072 20883057
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Fleck PR Wilson CA Mekki Q Alogliptin Study 010 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 2008 31 12 2315 2317 18809631
   PubMed Web of Science ®Google Scholar
• Brehm MA Shultz LD Greiner DL Humanized mouse models to study human diseases Curr Opin Endocrinol Diabetes Obes 2010 17 2 120 125 20150806
   PubMedGoogle Scholar
• Zhang X Wang Z Huang Y Wang J Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice Diabetes Obes Metab 2011 13 4 337 347 21205126
   PubMed Web of Science ®Google Scholar
• Yin H Park SY Wang XJ Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin PLoS One 2013 8 6 e65777 23762423
   PubMed Web of Science ®Google Scholar
• Brissova M Fowler MJ Nicholson WE Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy J Histochem Cytochem 2005 53 9 1087 1097 15923354
   PubMed Web of Science ®Google Scholar
• Perl S Kushner JA Buchholz BA Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating J Clin Endocrinol Metab 2010 95 10 E234 E239 20660050
   PubMed Web of Science ®Google Scholar
• Moritoh Y Takeuchi K Asakawa T Kataoka O Odaka H Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice Eur J Pharmacol 2008 588 2–3 325 332 18499100
   PubMed Web of Science ®Google Scholar
• Inaba W Mizukami H Kamata K Takahashi K Tsuboi K Yagihashi S Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats Eur J Pharmacol 2012 691 1–3 297 306 22820107
   PubMed Web of Science ®Google Scholar
• Levitt HE Cyphert TJ Pascoe JL Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice Diabetologia 2011 54 3 572 582 20936253
   PubMed Web of Science ®Google Scholar
• Diiorio P Jurczyk A Yang C Hyperglycemia-induced proliferation of adult human beta cells engrafted into spontaneously diabetic immunodeficient NOD-Rag1null IL2rγnull Ins2 Akita mice Pancreas 2011 40 7 1147 1149 21926555
   PubMed Web of Science ®Google Scholar